Targeting Brain Cholesterol Metabolism - A First-In-Class Treatment for Dravet Syndrome

Soticlestat is a first-in-class therapy under clinical development for pediatric epilepsy, with a particular focus on Lennox Gastaut and Dravet Syndromes. This preclinical study evaluated the anticonvulsant and disease-modifying potential in a mouse model of infection-induced acquired seizures. Notably, soticlestat demonstrated robust suppression of seizure presentation in vivo.